SUSVIMO

Everywhere You Go / Everywhere They Go

Creative Directors: Ryan Goldberg, Ed Stehlin
Art Directors: Olivia Acerra, Madison Grube, Yunuen Sigler
Copywriters: Steven Su, Matthew Ingardia, Kelly Slonaker

Susvimo is an ocular implant that delivers ranibizumab continuously over the course of 6 months, providing an alternative for nAMD patients who were previously receiving monthly injections. Its emergence in the market sought to dramatically improve the quality of life for patients, giving them the ability to take their care Everywhere They Go, versus being tethered to monthly doctor’s appointments.

Susvimo first launched in October of 2021, but effectively relaunched in October of 2022 with a new campaign for both HCP and DTC. The below work reflects the core materials of the new campaign: Everywhere You Go (DTC) / Everywhere They Go (HCP).

For patients with nAMD, SUSVIMO is the first and only twice-yearly treatment. In these patient-facing pieces, we’ve elevated this benefit with our Everywhere You Go campaign, including on our website (not shown), Welcome Kit, Patient Consideration Brochure, Emails, and Banner Ads. And with new, full testimonials from actual SUSVIMO patients, we’ve been able to showcase the real and meaningful changes this treatment can make.

Patient Materials

HCP-facing materials were developed to highlight the innovative technology that makes SUSVIMO a first-of-its-kind treatment. Our IVA/HCP website, and Clinical Leave Behind were all built on distinguishing SUSVIMO as a long-acting treatment with proven clinical results that can go with patients Everywhere They Go.

HCP Materials

Campaign Launch Twitter Video Post

Efficacy Twitter Video Post

The AAO convention served as the first opportunity for HCPs to witness the new Susvimo campaign. We built a presence for Susvimo within a shared booth for Genentech’s ophthalmology franchise, including Susvimo, Vabysmo, and Lucentis.

Susvimo